JNJ - Gilead Sciences Battles Rising Threat of Drug Counterfeiting Initiates Legal Actions | Benzinga
Gilead Sciences Inc (NASDAQ: GILD) faces a severe threat from the rise in drug counterfeiting, a global issue highlighted by the World Health Organization's staggering estimate of up to $431 billion in counterfeit drugs annually.
In the U.S. alone, incidents of counterfeiting surged by 17% in 2022, totaling 2,121 reported cases, CNBC noted, citing the Pharmaceutical Security Institute.
The company's commitment to combat this issue was underscored by filing a lawsuit in July 2021 against 161 defendants, including pharmacies and wholesale ...